Gaviscon Double Action tab. chewing # 24 (mint)
Package quantity, pcs:
12
24
Category
Preparations for the gastrointestinal tract
,
Ulcer and gastritis
,
Antacids
Scope of the drug
Gastrointestinal tract
Release form
Tablet
Manufacturer country
Great Britain
Package quantity, pcs
24
Dosage form
Round, flat, two-layer tablets with beveled edges and mint smell.
One layer is pink with small blotches of a darker color, the other is white.
On one side of the tablet: the image of a circle and a sword, on the other side: GDA250.
Structure
One chewable tablet contains:
active ingredients: sodium alginate 250 mg, sodium bicarbonate 106.5 mg, calcium carbonate 187.5 mg
excipients: mannitol 598.799 mg, macrogol-20000 30 mg, copovidone 33.75 mg, acesulfame potassium 5.863 mg, aspartame 5.863 mg, dye azorubin (11012) 0.375 mg, mint flavor 18.75 mg, xylitol (DC) 100 mg, magnesium stearate 6.75-12.6 mg.
pharmachologic effect
This drug is a combination of alginate and antacids (calcium carbonate and sodium bicarbonate).
When ingested, the active ingredients of Gaviscon® Double Action quickly react with the acidic contents of the stomach. This forms an alginate gel with a pH value close to neutral. The gel forms a protective barrier on the surface of the stomach contents, preventing the occurrence of gastroesophageal reflux (reflux of stomach contents into the esophagus). In severe cases of reflux (regurgitation), the gel is thrown into the esophagus ahead of the rest of the gastric contents, where it reduces irritation of the esophageal mucosa.
Calcium carbonate quickly neutralizes the hydrochloric acid in gastric juice, relieving heartburn and indigestion.
This effect is enhanced by the presence of sodium bicarbonate in the preparation, which also has a neutralizing effect.
The total acid-neutralizing activity of the drug in a minimum dose of 2 tablets is approximately 10 mEq.
Pharmacokinetics
The drug does not have systemic bioavailability (not absorbed).
Side effects
Immune system disorders: of unknown frequency - anaphylactic and anaphylactoid reactions, hypersensitivity reactions (urticaria).
Disturbances from the respiratory system, chest and mediastinal organs: of unknown frequency - respiratory effects (bronchospasm).
If any of the side effects indicated in the instructions are aggravated, or if you notice other side effects not listed in the instructions, inform your doctor.
Selling features
Available without a prescription
Special conditions
In a dose of two tablets, the sodium content is 110.75 mg (4.82 mmol).
This should be taken into account when it is necessary to adhere to a diet with limited salt content, for example, with congestive heart failure and mild renal failure.
Each dose of two tablets contains 150 mg (3.75 mmol) calcium.
Therefore, care should be taken when treating patients with hypercalcemia, nephrocalcinosis, and urolithiasis with the formation of calcium oxalate stones.
Due to the aspartame content, this drug should not be used in patients with phenylketonuria.
Gaviscon® Dual Action contains antacids that can mask the symptoms of serious gastrointestinal diseases.
A decrease in the effectiveness of the drug in patients with low acidity of gastric juice is possible.
In patients with gastroenteritis or suspected renal failure, there is an increased risk of hypernatremia with the drug.
You should not use the drug for a long time, if symptoms persist after 7 days of taking the drug, you should consult a doctor to review therapy.
Influence on the ability to drive vehicles and mechanisms:
The drug does not affect the ability to drive vehicles and mechanisms, as well as to engage in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.
Show
Name ENG
GAVISCON DOUBLE ACTION
Clinical and pharmacological group
Antacid drug
ATX code
Other antiulcer drugs
Dosage
187.5mg + 250mg + 106.5mg
Structure
active ingredients: sodium alginate 250 mg, sodium bicarbonate 106.5 mg, calcium carbonate 187.5 mg
excipients: mannitol 598.799 mg, macrogol-20000 30 mg, copovidone 33.75 mg, acesulfame potassium 5.863 mg, aspartame 5.863 mg, dye azorubin (11012) 0.375 mg, mint flavor 18.75 mg, xylitol (DC) 100 mg, magnesium stearate 6.75-12.6 mg.
Indications
Treatment of symptoms of gastroesophageal reflux, such as sour belching, heartburn, dyspepsia (indigestion, feeling of heaviness in the stomach), occurring after meals, in patients with high acidity of gastric juice or during pregnancy
INN / Active ingredient
calcium carbonate, sodium bicarbonate, sodium alginate
Contraindications
Hypersensitivity to any component of the drug phenylketonuria (see section Special instructions") renal failure of moderate and severe severity children under 12 years of age.,
Carefully:
If you have the following diseases or conditions, you should consult your doctor before using the drug: hypercalcemia, nephrocalcinosis and urolithiasis with the formation of calcium oxalate stones (see the section "Special instructions")
congestive heart failure (see section "Special instructions")
renal failure of mild severity (see section "Special instructions").
Storage conditions and periods
At a temperature not higher than 30 degrees.
Expiration date: 2 years
Specifications
Category
Preparations for the gastrointestinal tract
,
Ulcer and gastritis
,
Antacids
Scope of the drug
Gastrointestinal tract
Release form
Tablet
Manufacturer country
Great Britain
Package quantity, pcs
24
Scope of application
Gastroenterology
Minimum age from
12 years
Way of introduction
Through the mouth
Vacation conditions
Without recipe
Brand name
Reckitt-Benckiser
The amount of the dosage form in the primary package
8 pcs.
Primary packaging type
Blister
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Reflux Esophagitis Treatment
Dosage form
Chewable tablets, [mint]
Expiration date in days
730
The target audience
Children
Package weight, g
40
Mode of application
:
Inside, after thorough chewing.
< br> Adults and children over 12 years old: 2-4 tablets after meals and before bedtime (up to 4 times a day).
Anatomical and therapeutic characteristics
:
A02BX Anti-ulcer and gastroesophageal reflux drugs others
Dosage (volume) of the substance in the preparation
:
1 tablet: sodium alginate 250 mg, sodium bicarbonate 106.5 mg, calcium carbonate 187.5 mg
Information on technical characteristics, delivery set, country of manufacture "